As RSV evolves, a two‑pronged antibody cocktail aims to stay ahead

As RSV evolves, a two‑pronged antibody cocktail aims to stay ahead

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent problem with current therapies for infants. RSV is a seasonal infection that circulates globally and can be especially dangerous for people at opposite ends of the age spectrum: infants and older adults. Vaccines are available for those who are 65 and …